Sign in
CompletedPhase 2

A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of colorectal brain metastases.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
Netherlands2 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
10 people enrolled
Started
4 Dec 2023
Ended
11 Jun 2025
Type of study
Interventional
Record updated
16 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Signed informed consent prior to any study-mandated procedure
  • Patients aged over 18 years old
  • All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment
  • Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions
  • Diagnosed with brain metastasis of colorectal origin and scheduled for a resection

Who cannot take part

  • History of any anaphylactic reaction; 7. Previous use of SGM-101
  • Previous use of SGM-101
  • Patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate)
  • Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma
  • Any condition that the investigator considers to be potentially jeopardizing the patient’s well-being or the study objectives (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead electrocardiogram (ECG)). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the performance of SGM-101 in the intraoperative detection of brain metastases of colorectal origin.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SGM-CBM: A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of colorectal brain metastases.
Record updated
16 October 2024